Appetite

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024

Retrieved on: 
Monday, January 29, 2024

CHICAGO, Jan. 29, 2024 /PRNewswire/ -- Bartesian, the award-winning cocktail machine serving premium cocktails on demand, today announced a new, strategic multi-year partnership with iHeartMedia, the leading audio media company in the U.S. and podcast publisher globally. The deal allows Bartesian to leverage iHeartMedia's multi-platform network, reaching a quarter of a billion monthly listeners, and their marquee experiential events to bring the home cocktail maker to new audiences. The news follows record Black Friday & Cyber Monday sales for Bartesian this past holiday season.

Key Points: 
  • CHICAGO, Jan. 29, 2024 /PRNewswire/ -- Bartesian , the award-winning cocktail machine serving premium cocktails on demand, today announced a new, strategic multi-year partnership with iHeartMedia , the leading audio media company in the U.S. and podcast publisher globally.
  • The news follows record Black Friday & Cyber Monday sales for Bartesian this past holiday season.
  • "After a monumental and record-breaking sales year for Bartesian in 2023, we're hyper focused on introducing new customers to the product on an even larger scale," said Ryan Close, Bartesian Founder & CEO.
  • With consumer trends continuing to shift toward more elevated home experiences, Bartesian is the perfect solution for the at-home cocktail drinker and host.

Corbin Advisors Releases Q4’23 Inside The Buy-Side® Industrial Sentiment Survey®

Retrieved on: 
Thursday, January 18, 2024

Corbin Advisors, a strategic consultancy accelerating value realization globally, today released its quarterly Industrial Sentiment Survey®.

Key Points: 
  • Corbin Advisors, a strategic consultancy accelerating value realization globally, today released its quarterly Industrial Sentiment Survey®.
  • The survey, part of Corbin Advisors’ Inside The Buy-Side® flagship research publication, was conducted from December 4, 2023 to January 10, 2024, and is based on responses from 35 institutional investors and sell-side analysts globally who actively cover the Industrial sector.
  • Beginning in Q1’23, our quarterly sentiment surveys have found a continuing easing of bearish industrial investor sentiment while at the same time, perceived executive tone has been commensurately characterized as less bullish.
  • “Expectations for broad-based industrial weakness is a prominent theme throughout our survey, resulting in investors continuing to prioritize margins at higher levels than growth at this time,” said Rebecca Corbin, Founder and CEO of Corbin Advisors.

K1 Speed to Open Traverse City Indoor Go-Kart Racing Center in 2024

Retrieved on: 
Thursday, January 25, 2024

TRAVERSE CITY, Mich., Jan. 25, 2024 /PRNewswire-PRWeb/ -- K1 Speed, the world's largest indoor go-kart racing operator, is delighted to announce today its forthcoming location in Traverse City, Michigan - marking the brand's second location in the Great Lakes State!

Key Points: 
  • New K1 Speed indoor go-kart racing center coming to Traverse City this summer.
  • TRAVERSE CITY, Mich., Jan. 25, 2024 /PRNewswire-PRWeb/ -- K1 Speed, the world's largest indoor go-kart racing operator, is delighted to announce today its forthcoming location in Traverse City, Michigan - marking the brand's second location in the Great Lakes State!
  • K1 Speed Traverse City, a franchised location, is anticipated to open late summer 2024 in Garfield Township at the Cherryland Center's former Sears building.
  • For more information about K1 Speed Traverse City and to sign up for upcoming updates, please visit: www.k1speed.com/traverse-city-location.html
    Founded in 2003, K1 Speed is the world's largest indoor electric kart racing operator, with 86 locations in seven different countries and 29 states.

StePacPPC's New Sustainable Packaging Boosts Exotic Mushroom Longevity

Retrieved on: 
Wednesday, January 24, 2024

TEFEN, Israel, Jan. 24, 2024 /PRNewswire/ -- Fresh produce packaging pioneers StePacPPC has customized its award-winning modified atmosphere packaging (MAP) films to preserve fresh whole and sliced white mushrooms, and whole exotic mushrooms, such as oyster, lion's mane, shiitake, portabella and more. The lean MAP system fulfills consumer demands for sustainable packaging that slows deterioration and dramatically reduces waste of this highly perishable item.

Key Points: 
  • The lean MAP system fulfills consumer demands for sustainable packaging that slows deterioration and dramatically reduces waste of this highly perishable item.
  • Growers and shippers are constantly grappling with these challenges, striving to improve mushroom storage capabilities and curb waste.
  • StePacPPC's latest advancement in its packaging formats is designed specifically to maintain the freshness of whole and sliced white mushrooms, and whole exotic mushrooms.
  • These lean and sustainable packaging formats can optionally be produced with 30% recycled material to support a circular economy.

StePacPPC's New Sustainable Packaging Boosts Exotic Mushroom Longevity

Retrieved on: 
Wednesday, January 24, 2024

TEFEN, Israel, Jan. 24, 2024 /PRNewswire/ -- Fresh produce packaging pioneers StePacPPC has customized its award-winning modified atmosphere packaging (MAP) films to preserve fresh whole and sliced white mushrooms, and whole exotic mushrooms, such as oyster, lion's mane, shiitake, portabella and more. The lean MAP system fulfills consumer demands for sustainable packaging that slows deterioration and dramatically reduces waste of this highly perishable item.

Key Points: 
  • The lean MAP system fulfills consumer demands for sustainable packaging that slows deterioration and dramatically reduces waste of this highly perishable item.
  • Growers and shippers are constantly grappling with these challenges, striving to improve mushroom storage capabilities and curb waste.
  • StePacPPC's latest advancement in its packaging formats is designed specifically to maintain the freshness of whole and sliced white mushrooms, and whole exotic mushrooms.
  • These lean and sustainable packaging formats can optionally be produced with 30% recycled material to support a circular economy.

Pheburane® (sodium phenylbutyrate) is now on the Medicaid Preferred Drug List in 10 states

Retrieved on: 
Tuesday, January 23, 2024

Pheburane® is the safe, effective and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain UCDs.

Key Points: 
  • Pheburane® is the safe, effective and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain UCDs.
  • With the continued favorable commercial and Medicaid coverage updates, Pheburane® is reaching more patients all over the USA while being recognized as a first-line therapy by health authorities in key states.
  • UCDs are rare, chronic, genetic conditions that can be fatal if left untreated, and can impact children from the time of birth.
  • UNIK Support offers specialized services including a copay savings program, patient care liaison services, mail order pharmacy and other support services.

Ares, Eurazeo, Barings Among Top 2023 European Direct Lenders - Lower Mid Market Deals Account for 80% of Transactions Despite Record Unitranche Size Raised

Retrieved on: 
Tuesday, January 23, 2024

The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector.

Key Points: 
  • The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector.
  • Additionally, the report explores overall deal flow in 2023 and lender activity in ESG-related deals.
  • European direct lending activity in 2023 totalled 680 deals with lower mid-market deals by far the most popular debt range, representing 80.5% of the market.
  • Unitranche deals dominated the market, making up 71.1% of the deals seen in 2023.

Ares, Eurazeo, Barings Among Top 2023 European Direct Lenders - Lower Mid Market Deals Account for 80% of Transactions Despite Record Unitranche Size Raised

Retrieved on: 
Tuesday, January 23, 2024

The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector.

Key Points: 
  • The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector.
  • Additionally, the report explores overall deal flow in 2023 and lender activity in ESG-related deals.
  • European direct lending activity in 2023 totalled 680 deals with lower mid-market deals by far the most popular debt range, representing 80.5% of the market.
  • Unitranche deals dominated the market, making up 71.1% of the deals seen in 2023.

BNP Paribas, Merrill Lynch and MSCI former executive joins fintech Premialab

Retrieved on: 
Tuesday, January 23, 2024

LONDON and DUBAI, UAE, Jan. 23, 2024 /PRNewswire/ --  Premialab announces the appointment of Philippe Jacson as Head of Business Development in Asia & Middle East. Based in Dubai, Mr. Jacson will lead the business development in this key market segment. Before joining Premialab, Mr. Jacson served a wide range of institutional clients investment banking leadership roles including MSCI, Merril Lynch, and BNP Paribas.

Key Points: 
  • Based in Dubai, Mr. Jacson will lead the business development in this key market segment.
  • Before joining Premialab, Mr. Jacson served a wide range of institutional clients investment banking leadership roles including MSCI, Merril Lynch, and BNP Paribas.
  • Mr. Jacson has over 20 years' experience in equity derivatives and index investment solutions.
  • Mr. Jacson holds an enginereing degree from Ecole Polytechnique and ENSAE in Paris.

U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations

Retrieved on: 
Friday, January 19, 2024

RARITAN, N.J., Jan. 19, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA® (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. BALVERSA® is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. This FDA action converts the April 2019 accelerated approval of BALVERSA® to a full approval based on the clinical and overall survival benefit observed in the Phase 3 THOR study. BALVERSA® is the first oral FGFR kinase inhibitor to be approved, and the first and only targeted treatment for patients with mUC and FGFR alterations.

Key Points: 
  • BALVERSA® is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
  • This FDA action converts the April 2019 accelerated approval of BALVERSA® to a full approval based on the clinical and overall survival benefit observed in the Phase 3 THOR study.
  • BALVERSA® is the first oral FGFR kinase inhibitor to be approved, and the first and only targeted treatment for patients with mUC and FGFR alterations.
  • This model is part of the Company's ongoing commitment to provide high-quality products, services, access, and support to healthcare professionals and patients.